Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II
Public ClinicalTrials.gov record NCT01172821. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (2.5 and 5 µg Once Daily) Compared With Placebo and Salmeterol HFA MDI (50 µg Twice Daily) Over 24 Weeks in Moderate Persistent Asthma
Study identification
- NCT ID
- NCT01172821
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Enrollment
- 1,032 participants
Conditions and interventions
Conditions
Interventions
- 50 mcg salmeterol HFA MDI Drug
- placebo Drug
- tiotropium Respimat® high dose Drug
- tiotropium Respimat® low dose Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2010
- Primary completion
- Oct 31, 2012
- Completion
- Oct 31, 2012
- Last update posted
- Jun 8, 2014
2010 – 2012
United States locations
- U.S. sites
- 18
- U.S. states
- 13
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 205.419.01058 Boehringer Ingelheim Investigational Site | Los Angeles | California | — | — |
| 205.419.01053 Boehringer Ingelheim Investigational Site | Stockton | California | — | — |
| 205.419.01061 Boehringer Ingelheim Investigational Site | Centennial | Colorado | — | — |
| 205.419.01066 Boehringer Ingelheim Investigational Site | Denver | Colorado | — | — |
| 205.419.01064 Boehringer Ingelheim Investigational Site | Panama City | Florida | — | — |
| 205.419.01060 Boehringer Ingelheim Investigational Site | Winter Park | Florida | — | — |
| 205.419.01068 Boehringer Ingelheim Investigational Site | Novi | Michigan | — | — |
| 205.419.01054 Boehringer Ingelheim Investigational Site | Plymouth | Minnesota | — | — |
| 205.419.01062 Boehringer Ingelheim Investigational Site | St Louis | Missouri | — | — |
| 205.419.01070 Boehringer Ingelheim Investigational Site | Bozeman | Montana | — | — |
| 205.419.01067 Boehringer Ingelheim Investigational Site | Skillman | New Jersey | — | — |
| 205.419.01071 Boehringer Ingelheim Investigational Site | Raleigh | North Carolina | — | — |
| 205.419.01055 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | — | — |
| 205.419.01065 Boehringer Ingelheim Investigational Site | Portland | Oregon | — | — |
| 205.419.01069 Boehringer Ingelheim Investigational Site | Greenville | South Carolina | — | — |
| 205.419.01056 Boehringer Ingelheim Investigational Site | Union | South Carolina | — | — |
| 205.419.01063 Boehringer Ingelheim Investigational Site | El Paso | Texas | — | — |
| 205.419.01051 Boehringer Ingelheim Investigational Site | San Antonio | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 107 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01172821, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 8, 2014 · Synced Apr 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01172821 live on ClinicalTrials.gov.